VHL and renal cell carcinoma: Taken together, our study shows that VHL-deficient RCC cells are synthetic lethal with anti-microtubule agents via disrupting mitotic progression and provides a rationale for potential drug combination with newly developed RCC targeted therapies, such as HIF inhibitors.